Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development of gastric cancer-among the world's deadliest forms of the disease.

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a frontrunner in ... Del-zota: Designed for DMD exon 44 skipping, this therapy has generated considerable excitement and could potentially ...

A vast search of natural diversity has led scientists at MIT’s McGovern Institute and the Broad Institute of MIT and Harvard ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

With further testing, discovery may offer new target for early detection and treatmentResearchers at Case Western Reserve ...